Moving along nicely here....
Spectral Medical Receives US$3 Million From Vantive
T.EDT | 4 hours agoTORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025.
The Tranche B advance further strengthens Spectral’s balance sheet and will be used to support ongoing regulatory and commercialization preparations, as well as general working capital requirements. Spectral does not anticipate requiring any additional funding – beyond the fully drawn senior secured promissory note as previously disclosed – to meet its upcoming key milestones, including U.S. FDA submission, and through to PMX commercialization.
“We appreciate Vantive’s continued support and are pleased to have closed the Tranche B advance,” said Chris Seto, Chief Executive Officer of Spectral Medical. “This non-dilutive capital enhances our liquidity and provides additional flexibility as we execute on our regulatory pathway and commercialization plans. With this funding in place, we remain focused on operational priorities.”
Under the terms of the promissory note, Vantive may advance funds up to US$10 million to Spectral in up to four separate tranches to support Spectral’s continued evidence generation strategy and path to commercialization of Toraymyxin™ (“PMX”). With the US$3 million Tranche B advance, together with the initial US$4 million Tranche A advance, the current cumulative draw of the promissory note is US$7 million.
A copy of the Agreement has been filed under Spectral’s profile on SEDAR+ at www.sedarplus.ca.
About Spectral
“We appreciate Vantive’s continued support and are pleased to have closed the Tranche B advance,” said Chris Seto, Chief Executive Officer of Spectral Medical. “This non-dilutive capital enhances our liquidity and provides additional flexibility as we execute on our regulatory pathway and commercialization plans. With this funding in place, we remain focused on operational priorities.”
Under the terms of the promissory note, Vantive may advance funds up to US$10 million to Spectral in up to four separate tranches to support Spectral’s continued evidence generation strategy and path to commercialization of Toraymyxin™ (“PMX”). With the US$3 million Tranche B advance, together with the initial US$4 million Tranche A advance, the current cumulative draw of the promissory note is US$7 million.
A copy of the Agreement has been filed under Spectral’s profile on SEDAR+ at www.sedarplus.ca.
About Spectral
The addressable market and the need for a high margin product by Vantive.
it's had a good run up I suspect some will take a profit here..I could see few cents getting shaved in the next few days
It's been very unpredictable because of poor volume in the past...
This is on pending FDA approval...still 8 months or so away
I'm always hesitant to post analyst reports but this was posted someplace else (Quoted word for word.)
I'd assume the projected jump from 2.00 to 3.25 would be the entry point of fund participation.
"Spectral Medical (EDT): Event-Driven/Episodic Pivot Opportunity as Re-Rating Process Begins
The set-up: Spectral Medical (EDT) announced game-changing news on August 12 (see Paradigm research note), which broke the stock out of a 5-year basing pattern. This event-driven catalyst, also known as an episodic pivot, supports a fundamental re-rating of the stock and the technical price action confirms that this process is commencing, making for an immediately actionable entry point for investors.
Hallmarks of a successful episodic pivot include a high-impact catalyst, clearer path to revenue/approval, a new/expanded buyer base, resolution of uncertainty and a shift in narrative. These events will also tend to drive a high-volume gap in the stock (known as a breakaway gap), which begins a trending phase as price begins to move toward (and often beyond) the new fundamental value.
Why Spectral meets the criteria of an episodic pivot breakout. EDT gapped up on 2.6M shares on August 13, representing a 2,417% increase over the prior day and 13x the 30-day average volume. The stock has since held above the breakaway gap zone after several days of healthy digestion with no loss of momentum and has now recaptured the anchored VWAP from the event. The name underwent a long period of investor neglect and skepticism due to past failed septic shock treatments, but that narrative is now poised to change.
Why does the fundamental mispricing opportunity exist? EDT does not have strong institutional sponsorship or index/ETF representation, so the market will be less efficient in pricing in good news. This creates an opportunity for active investors, whose job it is to exploit market inefficiencies.
Technical set-up – base breakout targets $2.00 then $3.25. EDT has completed a structural basing pattern with the gap up through the $0.85 horizontal resistance zone, putting $2.00 then $3.25 as the next major Fibonacci targets (fundamental target sits in between at $2.70).
Many such cases. We highlight a handful of case studies in this note to provide visual illustration of how these events tend to play out on the charts".
Let's get this done!!!!
I'd assume the projected jump from 2.00 to 3.25 would be the entry point of fund participation.
Paradigm's recent update.
"Spectral Medical (EDT): Event-Driven/Episodic Pivot Opportunity as Re-Rating Process Begins
The set-up: Spectral Medical (EDT) announced game-changing news on August 12 (see Paradigm research note), which broke the stock out of a 5-year basing pattern. This event-driven catalyst, also known as an episodic pivot, supports a fundamental re-rating of the stock and the technical price action confirms that this process is commencing, making for an immediately actionable entry point for investors.
Hallmarks of a successful episodic pivot include a high-impact catalyst, clearer path to revenue/approval, a new/expanded buyer base, resolution of uncertainty and a shift in narrative. These events will also tend to drive a high-volume gap in the stock (known as a breakaway gap), which begins a trending phase as price begins to move toward (and often beyond) the new fundamental value.
Why Spectral meets the criteria of an episodic pivot breakout. EDT gapped up on 2.6M shares on August 13, representing a 2,417% increase over the prior day and 13x the 30-day average volume. The stock has since held above the breakaway gap zone after several days of healthy digestion with no loss of momentum and has now recaptured the anchored VWAP from the event. The name underwent a long period of investor neglect and skepticism due to past failed septic shock treatments, but that narrative is now poised to change.
Why does the fundamental mispricing opportunity exist? EDT does not have strong institutional sponsorship or index/ETF representation, so the market will be less efficient in pricing in good news. This creates an opportunity for active investors, whose job it is to exploit market inefficiencies.
Technical set-up – base breakout targets $2.00 then $3.25. EDT has completed a structural basing pattern with the gap up through the $0.85 horizontal resistance zone, putting $2.00 then $3.25 as the next major Fibonacci targets (fundamental target sits in between at $2.70).
Many such cases. We highlight a handful of case studies in this note to provide visual illustration of how these events tend to play out on the charts".
Let's get this done!!!!
